Wang Elyn H, Corso Christopher D, Park Henry S, Chen Aileen B, Wilson Lynn D, Kim Anthony W, Decker Roy H, Yu James B
Department of Therapeutic Radiology, Yale School of Medicine.
Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center at Yale.
Am J Clin Oncol. 2018 Feb;41(2):152-158. doi: 10.1097/COC.0000000000000245.
To review trends in the use of postoperative radiotherapy (PORT) in the modern era for N0-N1 margin-negative non-small cell lung cancer (NSCLC) following surgical resection and evaluate the association between PORT dose and overall survival.
We performed a retrospective study of nonmetastatic stage II and III N0-N1 margin-negative NSCLC surgically treated patients within the National Cancer Data Base from 2003 to 2011. Cox proportional hazards regression was performed for multivariable analyses of overall survival and PORT dose. Radiation modalities included nonconformal beam radiation, 3-dimensional conformal radiation (3D-CRT), and intensity-modulated radiation therapy.
We identified 2167 (6.7%) and 30,269 (93.3%) patients with surgically resected stage II or III N0-N1 margin-negative NSCLC who were treated with and without PORT, respectively. The proportion of patients treated with PORT (dose range, 45 to 74 Gy) decreased from 8.9% in 2003 to 2006 to 4.1% in 2010 to 2011. Among patients receiving PORT, the use of high-dose (60 to 74 Gy) PORT rose throughout the study period, starting at 34.8% in 2003 to 2006 and rising to 49.3% in 2010 to 2011.Overall, patients who received PORT had worse survival (hazards ratio=1.30; 95% confidence interval, 1.20-1.40) compared with those not receiving PORT. This association was unchanged when limited to patients receiving modern treatment with 3-CRT or intensity-modulated radiation therapy (hazards ratio=1.35; 95% confidence interval, 1.10-1.65).
The use of PORT for N0-N1 margin-negative NSCLC decreased from 2003 to 2011. We found no evidence of benefit from PORT for resected N0-N1 margin-negative NSCLC, regardless of dose or technique. PORT should be approached with caution in this group of patients, regardless of radiotherapy technique.
回顾现代术后放疗(PORT)在手术切除后N0-N1切缘阴性非小细胞肺癌(NSCLC)中的应用趋势,并评估PORT剂量与总生存期之间的关联。
我们对2003年至2011年国家癌症数据库中接受手术治疗的非转移性II期和III期N0-N1切缘阴性NSCLC患者进行了一项回顾性研究。采用Cox比例风险回归对总生存期和PORT剂量进行多变量分析。放疗方式包括非适形束放疗、三维适形放疗(3D-CRT)和调强放疗。
我们分别确定了2167例(6.7%)和30269例(93.3%)接受手术切除的II期或III期N0-N1切缘阴性NSCLC患者,其中接受PORT和未接受PORT治疗的患者分别为上述例数。接受PORT治疗的患者比例(剂量范围45至74 Gy)从2003年至2006年的8.9%降至2010年至2011年的4.1%。在接受PORT治疗的患者中,高剂量(60至74 Gy)PORT的使用在整个研究期间有所增加,从2003年至2006年的34.8%开始,升至2010年至2011年的49.3%。总体而言,接受PORT治疗的患者与未接受PORT治疗的患者相比,生存期更差(风险比=1.30;95%置信区间,1.20-1.40)。当仅限于接受3-CRT或调强放疗现代治疗的患者时,这种关联没有改变(风险比=1.35;95%置信区间,1.10-1.65)。
2003年至2011年,PORT在N0-N1切缘阴性NSCLC中的应用减少。我们没有发现证据表明PORT对切除的N0-N1切缘阴性NSCLC有益,无论剂量或技术如何。对于这组患者,无论放疗技术如何,PORT的应用都应谨慎。